Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults Report of the quality standards subcommittee of the american academy of neurology and the American headache society

Neurology

Volumn 78, Issue 17, 2012, Pages 1346-1353

  Holland, S ^a   Silberstein, S D ^b   Freitag, F ^c   Dodick, D W ^d   Argoff, C ^e   Ashman, E ^f  

^a Armstrong State University   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Baylor Neuroscience Headache Center   (United States)

^d MAYO CLINIC   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Joint Base Elmendorf Richardson   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CYPROHEPTADINE; ESTRADIOL; ESTROGEN; FENOPROFEN; FLURBIPROFEN; HERBACEOUS AGENT; IBUPROFEN; INDOMETACIN; ISOFLAVONE DERIVATIVE; KETOPROFEN; MAGNESIUM; MEFENAMIC ACID; MIG 99; MONTELUKAST; N METHYLHISTAMINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PETASITES HYBRIDUS EXTRACT; PLACEBO; PROPRANOLOL; RIBOFLAVIN; SOY ISOFLAVONE DERIVATIVE; TANACETUM PARTHENIUM EXTRACT; TOPIRAMATE; UBIDECARENONE; UNCLASSIFIED DRUG; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ALOPECIA; ALTERNATIVE MEDICINE; ANGELICA SINENSIS; BLEEDING; CIMICIFUGA RACEMOSA; CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; EPISODIC MIGRAINE; ERUCTATION; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERBARIC OXYGEN; INJECTION SITE BURNING; INJECTION SITE PRURITUS; NAUSEA; PETASITES; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN ALLERGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

EID: 84860705677     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182535d0c     Document Type: Article

References (24)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; The American Migraine Prevalence and Prevention Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68:343-349. (Pubitemid 46184209)
2. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. Available at: Http://www.aan.com/professionals/practice/pdfs/gl0090.pdf. Accessed April 10, 2010.
3. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-762.
4. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-1345.
5. Millán-Guerrero RO, Isais-Millán R, Benjamín TH, Tene CE. N-alpha-methyl histamine safety and efficacy in migraine prophylaxis: Phase III study. Can J Neurol Sci 2006;33:195-199. (Pubitemid 43845173)
6. Millán-Guerrero RO, Isais-Millán R, Barreto-Vizcaíno S, et al. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: A randomized, controlled, doubleblind study. Eur J Neurol 2007;14:1079-1084. (Pubitemid 47459724)
7. Millán-Guerrero RO, Isais-Millán R, Barreto-Vizcaíno S, et al. Subcutaneous histamine versus topiramate in migraine prophylaxis: A double-blind study. Eur Neurol 2008;59:237-242. (Pubitemid 351561092)
8. Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000;48:223-226.
9. Brandes JL, Visser WH, Farmer MV, et al. Montelukast for migraine prophylaxis: A randomized, double-blind, placebo-controlled study. Headache 2004S;44:581-586. (Pubitemid 38780349)
10. Diener HC, Hartung E, Chrubasik J, et al; Study group. A comparative study of oral acetylsalicylic acid and metoprolol for the prophylactic treatment of migraine: A randomized, controlled, double-blind, parallel group phase III study. Cephalalgia 2001;21:120-128. (Pubitemid 32575475)
11. Benseñor IM, Cook NR, Lee IM, Chown MJ, Hennekens CH, Buring JE. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia 2001;21:175-183. (Pubitemid 32589033)
12. Silberstein SD, Olesen J, Bousser MG, et al; International Headache Society. The International Classification of Headache Disorders, 2nd Edition (ICHD-II): Revision of criteria for 82 Medication-overuse headache [erratum in 2006;26:360]. Cephalalgia 2005;25:460-465.
13. Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64:713-715. (Pubitemid 40261904)
14. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother 2002;56:283-288. (Pubitemid 35245311)
15. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: A doubleblind placebo-controlled crossover study. Neurology 2006; 67:2159-2163. (Pubitemid 46035469)
16. Eftedal OS, Lydersen S, Helde G, White L, Brubakk AO, Stovner LJ. A randomized, double blind study of the prophylactic effect of hyperbaric oxygen therapy on migraine. Cephalalgia 2004;24:639-644. (Pubitemid 39061253)
17. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: A randomized trial. Headache 2004;44:885-890. (Pubitemid 39362312)
18. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis-a double-blind, multicentre, randomized placebocontrolled dose-response study. Cephalalgia 2002;22: 523-532. (Pubitemid 36609346)
19. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg tid feverfew CO2-extract (MIG-99) in migraine prevention-a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005;25:1031-1041. (Pubitemid 41532108)
20. Pradalier A, Bakouche P, Baudesson G, et al. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: A double-blind study versus placebo. Cephalalgia 2001;21:818-822. (Pubitemid 34621527)
21. Grossman W, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Altern Med Rev 2001;6:303-310. (Pubitemid 32591866)
22. Lipton RB, Gobel H, Einhaupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004;63:2240-2244. (Pubitemid 40024330)
23. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355-363. (Pubitemid 46426410)
24. Scher AI, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: Results from the frequent headache epidemiology study. Cephalalgia 2010;30: 321-328.